Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Drugs Context ; 102021.
Article in English | MEDLINE | ID: mdl-34349821

ABSTRACT

BACKGROUND: Upper respiratory tract infections (URTIs) are a major cause of exacerbations in patients with chronic obstructive pulmonary disease (COPD). We assessed the effectiveness of Oscillococcinum® in the protection from URTIs in patients with COPD who had been vaccinated against influenza infection over the 2018-2019 winter season. METHODS: Patients (n=106; mean ± standard deviation age: 66.0 ± 10.3 years; 89.6% men) were randomized into two groups: group V received influenza vaccination only and group OV received influenza vaccination plus Oscillococcinum® (one oral dose per week from inclusion in the study until the end of follow-up, with a maximum of 6 months follow-up over the winter season). The primary endpoint was the incidence rate of URTIs (number of URTIs/1000 patient-treatment exposure days) during follow-up compared between the two groups. RESULTS: There was no significant difference in any of the demographic characteristics, baseline COPD, or clinical data between the two treatment groups (OV and V). The URTI incidence rate was significantly higher in group V than in group OV (2.9 versus 1.2 episodes/1000 treatment days, difference OV-V = -1.7; p=0.0312). There was a significant delay in occurrence of an URTI episode in the OV group versus the V group (mean ± standard error: 48.7 ± 3.0 versus 67.0 ± 2.8 days, respectively; p=0.0158). Limitations to this study include its small population size and the self-recording by patients of the number and duration of URTIs and exacerbations. CONCLUSION: Oscillococcinum may decrease the incidence rate and delay the appearance of URTIs in patients with COPD.

2.
Homeopathy ; 102(2): 139-44, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23622264

ABSTRACT

BACKGROUND: Mammary inflammation in dairy cows is a widespread problem in dairy farming resulting in significant economic and welfare concerns. Dolisovet (Belladonna 1dH, Calendula MT, Echinacea 1dH, Dulcamara 1cH) a homeopathic medicine, licensed in France and indicated for the restoration of mammary function in cows is presented as a 10 g tube of ointment for intramammary use. METHOD: A prospective, uncontrolled, observational pilot study involving the collection and analysis of data from 31 udder quarters identified as being inflamed by an automated milking system (AMS) was conducted to evaluate the effect of Dolisovet on selected parameters of mammary inflammation. Inflamed quarters were identified when milk quality started to deteriorate, via an alert generated by the AMS, on the basis of electrical conductivity (EC). Milk yield and EC were retrieved five to seven days prior to the AMS alert, on the day of and for the following seven days. Dolisovet was administered twice daily for two consecutive days, commencing on the day of the AMS alert. RESULTS: A significant reduction in EC was observed 4-7 days following the first treatment. An increase in milk yield was also observed following the first treatment. CONCLUSION: Dolisovet may have a beneficial therapeutic effect in the early stages of udder inflammation and for restoring udder health and function. This medicine may be an effective first line treatment for sub-clinical bovine mastitis, reducing the need for antibiotics. Randomised, controlled studies should be undertaken to further investigate this possibility.


Subject(s)
Mastitis, Bovine/drug therapy , Materia Medica/pharmacology , Plant Extracts/therapeutic use , Animals , Cattle , Female , France , Pilot Projects , Prospective Studies
3.
Am J Clin Nutr ; 82(2): 467-70, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16087994

ABSTRACT

BACKGROUND: Serotonin (5-hydroxytryptamine; 5-HT) is a key mediator in the control of food intake and is probably involved in the etiology of anorexia nervosa. An association between a polymorphism of the 5-HT receptor (5-HT2A) gene promoter (-1438G/A) and anorexia nervosa has been reported. OBJECTIVE: We investigated the relation between the -1438G/A polymorphism of the 5-HT(2A) gene and the energy and macronutrient intakes of children and adolescents. DESIGN: This cross-sectional study included 370 children and adolescents aged 10-20 y (176 boys and 194 girls from 251 families) drawn from the Stanislas Family Study. Energy and macronutrient intakes were assessed by using 3-d food records. The -1438G/A polymorphism was analyzed by polymerase chain reaction and then by Hpa II digestion. RESULTS: In the overall group, after adjustment for age, sex, weight, height, and family correlation, the A allele was significantly associated with lower energy (P for trend = 0.045) and with total, monounsaturated, and saturated fat intakes expressed in g/d (P for trend = 0.007, 0.005, and 0.006, respectively). Subjects with the GA genotype had intermediate values. In addition, genotype x sex and genotype x age interactions were not significant. CONCLUSIONS: The 5-HT2A gene polymorphism in the promoter region is associated with energy and fat intakes in young people. This could be explained by the role of the serotonergic system as a determinant of food intakes and eating behavior.


Subject(s)
Eating , Polymorphism, Genetic , Receptor, Serotonin, 5-HT2A/genetics , Adolescent , Adult , Child , Cross-Sectional Studies , Female , Humans , Male , Promoter Regions, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...